Robin Kate Kelley
罗宾·凯特·凯利
MD
Professor of Clinical Medicine; Helen Diller Family Comprehensive Cancer Center临床医学教授；海伦·迪勒家族综合癌症中心
👥Biography 个人简介
Robin Kate Kelley, MD is Professor of Clinical Medicine at UCSF Helen Diller Family Comprehensive Cancer Center and a leading investigator in biliary tract cancer and hepatocellular carcinoma. She contributed to the TOPAZ-1 trial establishing durvalumab plus gemcitabine/cisplatin as a new first-line standard for advanced biliary tract cancer and leads numerous early-phase immunotherapy and targeted therapy trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
TOPAZ-1 — Immunotherapy in First-Line Biliary Tract Cancer
Key investigator in the TOPAZ-1 phase III trial demonstrating that adding durvalumab to gemcitabine/cisplatin improved overall survival in advanced biliary tract cancer, establishing a new first-line immunotherapy-based standard.
Early-Phase Trial Leadership in Hepatobiliary Cancers
Leads a broad portfolio of phase I/II trials at UCSF exploring novel immunotherapy combinations, antibody-drug conjugates, and targeted agents in biliary tract cancer and HCC.
Representative Works 代表性著作
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1)
NEJM Evidence (2022)
Phase III trial establishing durvalumab plus gemcitabine/cisplatin as a new first-line standard, improving overall survival compared with chemotherapy alone in advanced biliary tract cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 罗宾·凯特·凯利 的研究动态
Follow Robin Kate Kelley's research updates
留下邮箱，当我们发布与 Robin Kate Kelley（University of California, San Francisco (UCSF)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment